Prescribing Information

ALECENSA®(alectinib)

Avastin® (bevacizumab)

Esbriet® (pirfenidone)

GAZYVARO® (obinutuzumab)

HEMLIBRA®(emicizumab)

Herceptin® (trastuzumab) IV

Herceptin® (trastuzumab) SC

Kadcyla®(trastuzumab emtansine)

OCREVUS®(ocrelizumab)

Perjeta® (pertuzumab)

Polivy® (polatuzumab vedotin)

RoACTEMRA®(tocilizumab) RA/GCA

RoACTEMRA® (tocilizumab) pJIA/sJIA

RoACTEMRA® (tocilizumab) CRS

Tecentriq®(atezolizumab) Lung Cancer

Tecentriq®(atezolizumab) mTNBC

Tecentriq®(atezolizumab) mUC

 

IV, intravenous; SC, subcutaneous; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; RA, rheumatoid arthritis; GCA, giant cell arteritis; pJIA, polyarticular juvenile idiopathic arthritis; sJIA, systemic juvenile idiopathic arthritis; NSCLC, Non-small-cell lung carcinoma; UC, urothelial carcinoma; mTNBC, metastatic triple-negative breast cancer

For the Summary of Product Characteristics for all Roche products available in the UK please see www.medicines.org.uk/emc.

 

M-GB-00001493

Date of preparation: September 2020